The CHARM program: The effects of candesartan for the management of patients with chronic heart failure

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 1, 2009, Pages 9-16

  McKelvie, Robert S ^a  

^a HHSC General Division   (Canada)

Author keywords

Angiotensin receptor blocker; Candesartan; Clinical trial; Heart failure; Heart failure therapy; Systolic dysfunction

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CREATININE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; POTASSIUM; SPIRONOLACTONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ANGIONEUROTIC EDEMA; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; REVIEW; RISK REDUCTION; SIDE EFFECT; SUDDEN DEATH; CHRONIC DISEASE; FEMALE; MALE; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES; TREATMENT OUTCOME;

EID: 60549091003     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.1.9     Document Type: Review

References (50)

1. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. 26, 1115-1140 (2005).
2. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the diagnosis and management of chronic heart failure in the adult-summary article: a report of the American College of Cardiology/ American Heart Association TaskForce on practice guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation 20, 1825-1852 (2005).
3. Ceia F, Fonseca C, Mota T et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur. J. Heart Fail. 4, 531-539 (2002).
4. Owan TE, Redfield MM. Epidemiology of Diastolic Heart Failure. Prog. Cardiovasc. Dis. 47(5), 320-332 (2005).
5. McKelvie RS. Cardiovascular disorders: heart failure. Clin. Evid. 12, 115-143 (2004).
6. Flather M, Yusuf S, Kober L et al.; the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355, 1575-1581 (2000).
7. Brophy JM, Joseph L, Rouleau JL. β-blockers in congestive heart failure: a Bayesian meta-analysis. Ann. Intern. Med. 134, 550-560 (2001).
8. Whorlow SL, Krum H. Meta-analysis of effect of β-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure. Am. J. Cardiol. 86, 886-889 (2000).
9. Packer M, Coats A, Fowler MB. Effect of Carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651-1658 (2001).
10. Pitt B, Zannad F, Remme WJ et al.; the Randomized Aldactone Evaluation Study Investigators. The effects of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709-717 (1999).
11. Schaufel M, Swedberg K, Koster M et al. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden: data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur. Heart J. 25, 300-307 (2005).
12. Lee DS, Austin PC, Rouleau JL et al. Predicting mortality among patients hospitalized for heart failure. Derivation and validation of a clinical model. JAMA 290(19), 2581-2587 (2003).
13. Pauls WJ, Tschope G, Sanderson JE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J. 20, 2539-2550 (2007).
14. Owan, TE, Hodge DO, Herges BS et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 355, 251-258 (2006).
15. Bhatia RS, TU JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med. 355, 260-269 (2006).
16. Massie BM, Fabi MR. Clinical trials in diastolic heart failure. Prog. Cardiov. Dis. 47(6), 389-395 (2005).
17. Bart BA, Ertl G, Held P et al. Contemporary management of patients with left ventricular systolic dysfunction: results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur. Heart J. 20, 1182-1190 (1999).
18. Jorde UP, Ennezat PV, Lisker J et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE mediated formation of angiotensin II in chronic heart failure. Circulation 10, 844-846 (2000).
19. Urata H, Healy-B, Stewart KW et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. 66, 883-890 (1990).
20. Macfadyen RJ, Lee AF, Morton JJ et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE-inhibttor treatment in cardiac failure? Heart. 82, 57-61 (1999).
21. Swedberg K, Pfeffer M, Granger C et al.; the Charm-Program Investigators. Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) - rationale and design. J. Card. Fail. 5, 276-282 (1999).
22. Sever P. Candesartan cilextil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J. Hum. Hypertens. 11(Suppl.2), S91-S95 (1997).
23. Van Lier JJ, Van Heiningen PNM, Sunzel M. Absorption metabolism and excretion of candesartan and candesartan cilexetil in healthy volunteers. J. Hum. Hypertens. 11(Suppl.2), S27-S28 (1997).
24. Hübner R, Högemann AM, Sunzel M et al. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J. Hum. Hypertens. 11(Suppl. 2), S19-S25 (1997).
25. 1H-benzimidazole-7-carboxylate (TCV-116). J. Pharmacol. Exp. Ther. 266, 114-120 (1993).
26. Nishikawa K, Naka T, Chatani F, Yoshimura Y. Candesartan cilexetil: a review of its predinical pharmacology. J. Hum. Hypertens. 11(Suppl. 2), S9-S17 (1997).
27. Ojima M, Inada Y, Shibouta Y et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur. J. Pharmacol. 319, 137-146 (1997).
28. Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol. Cell. Endocrinol. DOI: 10.1016/j.mce.2008.06.006 (2008).
29. Belz GG, Malerczyk C, Roll S et al. Angiotensin-II antagonist and radiogland receptor assay following various doses of candesartan cilextil in humans. J. Hypertens. 14(Suppl. 1), S134 (1996).
30. Malerczyk C, Fuchs B, Belz GG et al. Angiotensin II antagonist and plasma radioreceptor-kinetics of candesartan in man. Br. J. Clin. Pharmacol. 45, 567-573 (1998).
31. Granger CB, Ertl G, Kuch J et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am. Heart J. 139, 609-617 (2000).
32. Mitrovic V, Willenbrock R, Miric M et al. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones and clinical symptoms in patient with congestive heart failure. Am. Heart. J. 145, D1-D9 (2004).
33. Riegger GAJ, Buozo H, Petr P et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilextil. Circulation 100, 2224-2230 (1999).
34. Matsumori A; the Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) study investigators. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur. J. Heart. Fail. 5, 669-677 (2003).
35. McKlivie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunciton (RSOLVD) Pilot Study. The RESOLVD Pilot Study Investigators. Circulation 100, 1056-1064 (1999).
36. McKelvie RS, Rouleau JL, White M et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodeling in patients with congestive heart failure. Eur. Heart. J. 24, 1727-1734 (2003).
37. Granger CB, McMurray JJV, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative Trial. Lancet 362, 772-776 (2003).
38. McMurray JJV, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added Trial. Lancet 362, 767-771 (2003).
39. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
40. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall Program. Lancet 561, 759-766 (2003).
41. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: The CHARM-Preserved Trial. Lancet 362, 777-781 (2003).
42. Young JB, Dunlap ME, Pfeffer MA et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM Low-Left Ventricular Ejection Fraction Trials. Circulation 110, 2618-2183 (2004).
43. Solomon SD, Wang D, Finn P et al. Effect of candesartin on cause-specific mortality in heart failure patients: The Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 110, 2180-2183 (2004).
44. Demers C, McMurray JJV, Swedberg K et al. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 294, 1794-1798 (2005).
45. Yusuf S, Ostergren JB, Gerstein HC et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 112, 48-53 (2005).
46. Ducharme A, Swedberg K, Pfeffer M et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Am Heart J. 151, 985-991 (2006).
47. O'Meara E, Lewis E, Granger C et al. Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Eur. J. Heart Fail. 7, 650-656 (2005).
48. O'Meara E, Solomon S, McMurray J et al. Effect of candesartan on New York Heart Association functional class: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur. Heart J. 25, 1920-1926 (2004).
49. Meredith PA, Östergren J, Anand I et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity) program. J. Am. Coll. Cardiol. 52, 2000-2007 (2008).
50. Suskin N, McKelvie RS, Burns RJ et al. Glucose and insulin abnormalities relate to functional capacity in patients with patients wkh congestive heart failure. Eur. Heart J. 21, 1368-1375 (2000).